Exact's colorectal cancer test in trial at Mayo Clinic
This article was originally published in Clinica
The Mayo Clinic is to carry out a major prospective study of Exact Sciences' genomics-based colorectal cancer test with the support of a $4.9 million grant from the US National Cancer Institute. The test is based on analysis of DNA isolated from stool using the same sample processing technology as the PreGen-26 test launched at the end of May (see Clinica No 959, p 19).
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.